NEW YORK, Feb 12 (Reuters) - Sanofi-Aventis (SASY.PA: Quote, Profile , Research) said on Monday that U.S. health regulators have extended by three months their decision on whether to approve the French drugmaker’s highly anticipated weight loss drug, Acomplia.
